<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Cancer Studies</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D6085A0B-2215-4AB9-8A0A-40C36E50A37D"><gtr:id>D6085A0B-2215-4AB9-8A0A-40C36E50A37D</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000736"><gtr:id>53F8F09E-6005-4BCE-A244-B99B39D66D5E</gtr:id><gtr:title>Development of coincidence biodetectors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000736</gtr:grantReference><gtr:abstractText>Sophisticated research techniques have been used to show that it is possible to extract detailed information about the targets of drugs and target responses to drugs. At present, achieving this sort of information in a routine clinical setting is not practical. The proposal here is designed to exemplify a new technology that will ultimately satisfy the clinical need for this type of information. It is anticipated that the general use of the technology to be developed will impact broadly on the application of diagnostics to clinical decision making. The key contribution will be to defining which patients should receive which drugs - the personalised medicine agenda.</gtr:abstractText><gtr:technicalSummary>A significant challenge of biomedical research is the identification of molecular biomarkers that can be used in diagnosis, prognosis and in predicting and evaluating responses to treatments. The reliable assessment of these biomarkers in biological samples, particularly those from the clinic, has proved challenging; immunohistochemistry in this context is not well controlled, it is minimally quantified and frequently lacking in the specificity required. Prior work has established that a highly demanding, optical, coincidence detection approach can drive specificity to yield robust, spatially resolved and quantitative patient data. We aim to translate this principle of coincidence detection from a high-tech research process to a routine method. Here we will draw on pilot data to exemplify a novel coincidence biodetector for the analysis of pathophysiological events in tissue biopsies. The aim here is to exemplify an easy to use coincidence detection technology in a format, compatible with IHC.</gtr:technicalSummary><gtr:fund><gtr:end>2012-05-16</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>222444</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The patent covers the core techniology elaborated in the DPFS programme.</gtr:description><gtr:grantRef>G1000736</gtr:grantRef><gtr:id>2BA195DD-600A-46BA-901B-E564469D4ABF</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>jompv7mSDwM</gtr:outcomeId><gtr:patentId>WO 2011/161420 A3</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Coincidence detection</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We aim to develop coincidence detection in a 2D format compatible with IHC and retaining the specificity of a two-site assay. To achieve this we are developing the use of a novel bipartite coincidence biodetector created from two recombinant proteins, which drive the coincidence detection event. Both recombinant proteins are made up of a combination of two modular domains (recognition module and detection module) which are expressed in frame with a linker and simply purified as recombinant fusions from bacteria.
To achieve high specificity of recognition, the 'recognition modules' detect target molecules and/or their post-translational modifications. To generate specific readout signals we are exploiting DNA Binding Domains (DBDs) ('detection modules') of nuclear receptors (NRs) which bind specifically to their cognate DNA binding sites as obligate heterodimers. As a result, the signal is generated only when the two recognition modules bind their specific epitopes in close proximity.
The platform has been validated as a principle and we are now testing in fixed cellular samples.</gtr:description><gtr:id>7138E1C4-0722-4EA5-B9DF-810D7BD7B581</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>VdceoMMk1T3</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Coincidence Biodetector</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Pairs of recombinant proteins with combinations of recognition domains and detection domains that permit coincidence detection of paire of proximal antigens in biological samples. This would include a complex or a post-translational modification of a protein.</gtr:description><gtr:id>083F8E8F-C376-4A08-8A59-C351DF838BCE</gtr:id><gtr:impact>We have also now developed a single agent readout based on the established principles that provides a very sensitive assay.</gtr:impact><gtr:outcomeId>WdqcggmNUHJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Coincidence biodetectors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>694A8ED6-6428-4EC2-9AAA-887B50750932</gtr:id><gtr:title>Functional proteomic biomarkers in cancer.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/205f01e8a9297dda865f641de23a0ef6"><gtr:id>205f01e8a9297dda865f641de23a0ef6</gtr:id><gtr:otherNames>Larijani B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>56ddf5b1b08e61.89823509</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000736</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>